Actelion drug cuts brain lesions in MS patients
by on Aug.02, 2011, under Health and Fitness
Actelion's experimental multiple sclerosis drug ponesimod met its main goal in a mid-stage trial, giving the Swiss biotech's pipeline a much-needed boost.
View full post on Yahoo! Health News
